wetzoeker

S2.1 — ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS Internationaal Verdrag tegen doping in de sport

ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS

Including, but not limited to:

S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide, pegmolesatide)

S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon

S2.1.3 GATA inhibitors, e.g. K-11706

S2.1.4 Transforming growth factor beta (TGF-β) signalling inhibitors, e.g. luspatercept; sotatercept

S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO)

Regeling
Internationaal Verdrag tegen doping in de sport
Soort
Verdrag
Geldend vanaf
01-01-2026
BWB-id
BWBV0001829
Versie
2026-01-01_0

In de hele regeling · Officiële tekst op wetten.overheid.nl